As CCL2, HGF and CCL2/HGF treatment of breast cancer cells led to differences in glucose metabolism, we examined for expression of glycolytic proteins over time, including glucose transporter 1 (GLUT1) and rate limiting enzymes HK2, lactate dehydrogenase (LDHA) and pyruvate kinase M (PKM). The gene discussed is SLC2A1; the disease is breast carcinoma.